pituitary adenylate-cyclase-activating-peptide (6-38)

a potent antagonist of PACAP

Also Known As:

PACAP (6-38)

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Intercellular Signaling Peptides and Proteins: 30151
    - Nerve Growth Factors: 5170
      - Pituitary Adenylate Cyclase-Activating Polypeptide: 1138
        pituitary adenylate-cyclase-activating-peptide (6-38): 7
  - Nerve Tissue Proteins: 3
    - Neuropeptides: 6903
      - Pituitary Adenylate Cyclase-Activating Polypeptide: 1138
        pituitary adenylate-cyclase-activating-peptide (6-38): 7
    - Nerve Growth Factors: 5170
      - Pituitary Adenylate Cyclase-Activating Polypeptide: 1138
        pituitary adenylate-cyclase-activating-peptide (6-38): 7
- Peptides: 84029
Biological Factors: 2560
- Intercellular Signaling Peptides and Proteins: 30151
  - Nerve Growth Factors: 5170
    - Pituitary Adenylate Cyclase-Activating Polypeptide: 1138
      - pituitary adenylate-cyclase-activating-peptide (6-38): 7

Experts

1.	Farnham, Melissa M J: 2 articles (01/2016 - 01/2011)
2.	Pilowsky, Paul M: 2 articles (01/2016 - 01/2011)
3.	An, Meng-Qi: 1 article (12/2023)
4.	Dong, Li-Guo: 1 article (12/2023)
5.	Gu, Han-Ying: 1 article (12/2023)
6.	Li, Cheng-Jie: 1 article (12/2023)
7.	Liu, Chun-Feng: 1 article (12/2023)
8.	Mao, Cheng-Jie: 1 article (12/2023)
9.	Wang, Fen: 1 article (12/2023)
10.	Zhang, Jin-Bao: 1 article (12/2023)

Related Diseases

1.	Hyperalgesia 12/01/2023 - "Furthermore, we demonstrated that intrathecal microinjection of PACAP 6-38 (0.125, 0.5, 2 μg) dose-dependently ameliorated the mechanical and thermal hyperalgesia in 6-OHDA rats. " 05/01/2008 - "Taken together, these data demonstrate that blockade of the PAC(1)-R/PACAP complex by PACAP 6-38 can effectively attenuate thermal hyperalgesia and mechanical allodynia associated with inflammatory and neuropathic pain states. " 05/01/2008 - "PACAP 6-38 potently reduced mechanical allodynia in a neuropathic spinal nerve ligation model (77% +/- 15% maximal effect at 12 nmol, P < .01) and was also effective in reducing thermal hyperalgesia in the carrageenan model of inflammatory pain (89% +/- 17% maximal effect at 12 nmol, P < .01). "
2.	Pain (Aches) 05/01/2008 - "To better understand the role of PAC(1)-Rs in pain, PACAP 6-38, a PAC(1)-R antagonist, was evaluated in several inflammatory and neuropathic pain models after intrathecal (i.t.) administration. " 05/01/2008 - "Although nociceptive responses were also attenuated with PACAP 6-38 in a dose-dependent manner in models of chronic inflammatory and persistent pain, no effects on motor performance were observed at analgesic doses. " 05/01/2008 - "PACAP 6-38 potently reduced mechanical allodynia in a neuropathic spinal nerve ligation model (77% +/- 15% maximal effect at 12 nmol, P < .01) and was also effective in reducing thermal hyperalgesia in the carrageenan model of inflammatory pain (89% +/- 17% maximal effect at 12 nmol, P < .01). "
3.	Tachycardia (Tachyarrhythmias) 01/13/2016 - "PACAP or microglia antagonists (50 nl) (PACAP(6-38), 15 pmol; minocycline 10 mg/ml) microinjected bilaterally into RVLM had no effect on seizure-induced sympathoexcitation, pressor responses, or tachycardia but abolished the prolongation of QT interval. " 01/01/2011 - "The principal findings are that 1) the proportion of PACAP mRNA-containing C1 neurons is not different between normotensive and hypertensive rats, 2) intrathecal PACAP-38 causes a strain-dependent, sustained sympathoexcitation and tachycardia with variable effects on mean arterial pressure in normotensive and hypertensive rats, and 3) PACAP(6-38) effectively attenuated the effects of intrathecal PACAP-38, but had no effect alone, on any baseline variables. "
4.	Weight Gain 01/01/2013 - "In conclusion, PACAP 6-38 acts as a functional CARTp antagonist in vivo and blocks its effects on feeding and short term weight gain. "
5.	Neuralgia (Stump Neuralgia) 05/01/2008 - "To better understand the role of PAC(1)-Rs in pain, PACAP 6-38, a PAC(1)-R antagonist, was evaluated in several inflammatory and neuropathic pain models after intrathecal (i.t.) administration. " 05/01/2008 - "Taken together, these data demonstrate that blockade of the PAC(1)-R/PACAP complex by PACAP 6-38 can effectively attenuate thermal hyperalgesia and mechanical allodynia associated with inflammatory and neuropathic pain states. "

Related Drugs and Biologics

1.	Carrageenan
2.	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
3.	Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
4.	Oxidopamine (6 Hydroxydopamine)
5.	Messenger RNA (mRNA)
6.	Minocycline (Cyclops)
7.	Analgesics (Analgesic Drugs)
8.	Agar
9.	hyperoside

Related Therapies and Procedures

1.	Ligation